Remove companies grail-inc
article thumbnail

Illumina Brass Faces Shareholder Suit Over Grail Deal Debacle

Law 360

Food and Drug Administration Commissioner Scott Gottlieb, have been hit with a shareholder derivative suit in California federal court over their role in the biotech company's failed $8 billion deal to reacquire its cancer-detection company Grail Inc.

Court 40
article thumbnail

Chancery Bars Icahn Co. Use Of Some Illumina-Grail Docs

Law 360

Three Carl Icahn-controlled companies were ordered Tuesday to strike confidential details from a Delaware Chancery Court derivative suit targeting biotech giant Illumina Inc.'s s troubled $8 billion reacquisition of Grail Inc., finding an Icahn-tied Illumina director wrongly shared the information.

Court 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Icahn Says $8B Illumina-Grail Deal Caused Millions In Losses

Law 360

Carl Icahn alleges in a proposed securities class and derivative action filed in Delaware's Chancery Court that Illumina Inc.

Court 52
article thumbnail

Icahn Says Illumina Stance 'Insulting' As Proxy War Brews

Law 360

Carl Icahn on Wednesday said life sciences company Illumina Inc. is "insulting" the intelligence of its shareholders after the company defended its board and said it would not recommend Icahn's director nominees, the latest volley amid the billionaire's efforts to get Illumina to divest cancer biotech company Grail Inc.

52
article thumbnail

5th Circ. Asks Illumina, FTC For Update On EU Order's Impact

Law 360

The Fifth Circuit is asking Illumina Inc. and the Federal Trade Commission how a recent European Union order that Illumina sell off cancer detection company Grail Inc. will impact the FTC's suit challenging the $8 billion purchase.

40
article thumbnail

SEC Investigating Illumina-Grail Deal And Management Teams

Law 360

Illumina Inc. Securities and Exchange Commission is probing its 2020 reacquisition of Grail for $8 billion, including the conduct and pay of the companies' management. has revealed in a securities filing that the U.S.

40
article thumbnail

FTC Staff Say Full Pause Of Illumina Order Too Risky

Law 360

Federal Trade Commission staffers urged the commissioners to ensure Illumina remains separate from Grail Inc. while the company appeals an order to unwind their merger, arguing that keeping their operations apart will spur competition from rival cancer tests.

40